| 1 |
Qingling Zhang, Xiuhua Fu, Changzheng Wang, et al. Severe eosinophilic asthma in Chinese C-BIOPRED asthma cohort[J]. Clin Transl Med, 2022, 12(2): e710.
|
| 2 |
Bousquet Jean, Chanez Pascal, Lacoste Jean Yves, et al. Eosinophilic inflammation in asthma[J]. New Engl J Med, 323(15): 1033-1039.
|
| 3 |
Price David B, Rigazio Anna, Campbell Jonathan D, et al. Blood eosinophil count and prospective annual asthma disease burden: a UK cohort study[J]. Lancet Respirat Med, 2015, 3(11): 849-858.
|
| 4 |
GBD 2015 Chronic Respiratory Disease Collaborators. Global, regional，and national deaths, prevalence, disability-adjusted life years, and years lived with disability for chronic obstructive pulmonary disease and asthma, 1990-2015: a systematic analysis for the Global Burden of Disease Study[J]. Lancet Respir Med, 2017, 5(9): 691-706.
|
| 5 |
Roland KolEOSk, Alexander Kozhich, Masamichi Koike, et al. MEDI-563, a humanized anti-IL-5 receptor alpha mAb with enhanced antibody-dependent cell-mediated cytotoxicity function[J]. J Allergy Clin Immunol, 2010, 125(6): 1344-1353.
|
| 6 |
Laviolette M, Gossage DL, Gauvreau G, et al. Effects of benralizumab on airway eosinophils in asthmatic patients with sputum eosinophilia[J]. J Allergy Clin Immunol, 2013, 132: 1086-1096.
|
| 7 |
Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention, 2023. Updated July 2023. Available from:
URL
|
| 8 |
Bleecker ER, FitzGerald JM, Chanez P, et al. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β(2)-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial[J]. Lancet, 2016, 388(10056): 2115-2127.
|
| 9 |
FitzGerald JM, Bleecker ER, Nair P, et al. Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial[J]. Lancet, 2016, 388(10056): 2128-2141.
|
| 10 |
Kefang Lai, Dejun Sun, Ranran Dai, et al. Benralizumab efficacy and safety in severe asthma: A randomized trial in Asia[J]. Respir Med, 2024, doi: 10.1016/j.rmed.2024.107611.
|
| 11 |
林慧敏，谢佳星. 重症哮喘应用贝那利珠单抗治疗二例[J]. 结核与肺部疾病杂志，2022, 3(1): 80-86.
|
| 12 |
Menzies-Gow A, Gurnell M, Heaney LG, et al. Oral corticosteroid elimination via a personalised reduction algorithm in adults with severe, eosinophilic asthma treated with benralizumab (PONENTE): a multicentre, open-label, single-arm study[J]. Lancet Respir Med, 2022, 10(1): 47-58.
|
| 13 |
Jackson David J, Heaney Liam G, Humbert Marc, et al. Reduction of daily maintenance inhaled corticosteroids in patients with severe eosinophilic asthma treated with benralizumab (SHAMAL): a randomised, multicentre, open-label, phase 4 study[J]. Lancet, 2024, 403(10423): 271-281.
|
| 14 |
Alessandra Bettiol, Maria Letizia Urban, Roberto Padoan, et al. Benralizumab for eosinophilic granulomatosis with polyangiitis: a retrospective, multicentre, cohort study[J]. Lancet Rheumatol, 2023, 5(12): e707-e715.
|
| 15 |
Kliewer Kara L, Murray-Petzold Cristin, Collins Margaret H, et al. Benralizumab for eosinophilic gastritis: A phase 2, randomized, double-blind, placebo-controlled trial[J]. Lancet Gastroenterol Hepatol, 2023, 8(9): 803-815.
|